Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study

Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study

Abstract Introduction Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoagulant effect of dabigatran, and it was approved in Japan in September 2016. An all-case post-marketing surveillance is ongoing to collect data in Japanese patients treated with idarucizumab who h...

Full description

Bibliographic Details
Main Authors: Masahiro Yasaka, Hiroyuki Yokota, Michiyasu Suzuki, Hidesaku Asakura, Teiichi Yamane, Yukako Ogi, Kaori Ochiai, Daisuke Nakayama
Format: Article
Language:English
Published: Adis, Springer Healthcare 2020-03-01
Series:Cardiology and Therapy
Subjects:
Anticoagulant
Dabigatran
Emergency surgery
Hemorrhage
Idarucizumab
Japan
Online Access:https://doi.org/10.1007/s40119-020-00165-8

Internet

https://doi.org/10.1007/s40119-020-00165-8

Similar Items